Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects

被引：0
|
作者：
Jing Wang
Zhi-Yi Zhang
Sharon Lu
Dan Powers
Vikram Kansra
Xiaodong Wang
机构：
[1] TESARO,
[2] Inc.,undefined
来源：
Supportive Care in Cancer | 2019年 / 27卷
关键词：
Rolapitant; Antiemetics; Neurokinin-1 receptor antagonist; Drug interactions; Cytochrome P450;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：819 / 827
页数：8
相关论文
共 50 条
  • [41] EFFECT OF CYP2C8 AND CYP2C9 AND GENDER ON PIOGLITAZONE PHARMACOKINETICS IN HEALTHY VOLUNTEERS
    Roman, M.
    Ochoa, M. D.
    Talegon, M.
    Rivas, A.
    Prieto, R.
    Cabaleiro, T.
    Abad, F.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2013, 113 : 23 - 23
  • [42] MOCLOBEMIDE, A SUBSTRATE OF CYP2C19 AND AN INHIBITOR OF CYP2C19, CYP2D6, AND CYP1A2 - A PANEL STUDY
    GRAM, LF
    GUENTERT, TW
    GRANGE, S
    VISTISEN, K
    BROSEN, K
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (06) : 670 - 677
  • [43] Polymorphisms of CYP2C8, CYP2C9 and CYP2C19 and risk of coronary heart disease in Russian population
    Polonikov, Alexey
    Kharchenko, Alexander
    Bykanova, Marina
    Sirotina, Svetlana
    Ponomarenko, Irina
    Bocharova, Anna
    Vagaytseva, Kseniya
    Stepanov, Vadim
    Bushueva, Olga
    Churnosov, Mikhail
    Solodilova, Maria
    GENE, 2017, 627 : 451 - 459
  • [44] Suppression of CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5 activity by a cocktail of inflammatory cytokines
    Foster, John
    Webber, Guy
    Ormsby, Terry
    Cheung, Yen-Ling
    Paul, Danny S.
    Webber, Colin
    Waring, Adrian
    DRUG METABOLISM REVIEWS, 2016, 48 : 89 - 89
  • [45] The contribution of the enzymes CYP2D6 and CYP2C19 in the demethylation of artemether in healthy subjects
    Van Agtmael, MA
    Van der Graaf, CAA
    Dien, TK
    Koopmans, RP
    Van Boxtel, CJ
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1998, 23 (03) : 429 - 436
  • [46] The contribution of the enzymes CYP2D6 and CYP2C19 in the demethylation of artemether in healthy subjects
    M. A. Van Agtmael
    C. A. A. Van Der Graaf
    T. K. Dien
    R. P. Koopmans
    C. J. Van Boxtel
    European Journal of Drug Metabolism and Pharmacokinetics, 1998, 23 : 429 - 436
  • [47] Efficiency to detect PM of CYP2D6, CYP2C9, and CYP2C19 based on volunteers' phenotype and genotype.
    Masson, E
    Tassé, C
    Larouche, R
    Girard, B
    LeBel, M
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (02) : P40 - P40
  • [48] Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population
    Bozina, N
    Granic, P
    Lalic, Z
    Tramisak, I
    Lovric, M
    Stavljenic-Rukavina, A
    CROATIAN MEDICAL JOURNAL, 2003, 44 (04) : 425 - 428
  • [49] Allele Frequency of the Most Common Polymorphisms of CYP2C9, CYP2C19 and CYP2D6 Genes in a Chilean Population
    Solari, S.
    Lagos, M.
    Poggi, H.
    Miranda, C.
    Romeo, E.
    Engel, P.
    Rios, J. C.
    THERAPEUTIC DRUG MONITORING, 2009, 31 (05) : 661 - 661
  • [50] Genetic and phenotypic frequency distribution of CYP2C9, CYP2C19 and CYP2D6 in over 3200 Han Chinese
    He, Li
    Chen, Shaojun
    Li, Jingao
    Xie, Xiaoxue
    Huang, Lihua
    Kuang, Yun
    Xu, Kangwei
    Huang, Wanxia
    Zhao, Yanling
    Yang, Guoping
    Guo, Chengxian
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2020, 47 (10) : 1659 - 1663
12345